6533b7cffe1ef96bd125911f
RESEARCH PRODUCT
Mediterranean Diet Reduces the Adverse Effect of the TCF7L2-rs7903146 Polymorphism on Cardiovascular Risk Factors and Stroke Incidence
Valentina Ruiz-gutiérrezValentina Ruiz-gutiérrezMiguel A. MuñozM. Isabel CovasJosé V. SorlíJosé V. SorlíDolores CorellaDolores CorellaOscar ColtellOscar ColtellMiquel FiolEmilio RosJesús Rico-sanzXavier PintóMiguel ÁNgel Martínez-gonzálezMiguel ÁNgel Martínez-gonzálezJosé LapetraRamon EstruchRamon EstruchJosé I. GonzálezJosé I. GonzálezJulia WärnbergJulia WärnbergFernando ArósJordi Salas-salvadóPaula CarrascoPaula CarrascoJ. Alfredo MartínezJ. Alfredo MartínezEnrique Gómez-graciaEnrique Gómez-graciaJose M. OrdovasJose M. OrdovasCarolina Ortega-azorínCarolina Ortega-azorínLluis Serra-majemLluis Serra-majemsubject
Malemedicine.medical_specialtyCardiovascular and Metabolic RiskMediterranean dietEndocrinology Diabetes and MetabolismPopulationType 2 diabetesDiet MediterraneanGastroenterologylaw.inventionRandomized controlled triallawRisk FactorsDiabetes mellitusInternal medicineInternal MedicinemedicineOdds RatioHumanseducationTriglyceridesOriginal ResearchAgedAdvanced and Specialized Nursingeducation.field_of_studyPolymorphism Geneticbusiness.industryIncidenceHazard ratioOdds ratioFastingMiddle Agedmedicine.diseaseStrokeEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesFemalebusinessTCF7L2Transcription Factor 7-Like 2 Proteindescription
OBJECTIVE Transcription factor 7-like 2 (TCF7L2) polymorphisms are strongly associated with type 2 diabetes, but controversially with plasma lipids and cardiovascular disease. Interactions of the Mediterranean diet (MedDiet) on these associations are unknown. We investigated whether the TCF7L2-rs7903146 (C>T) polymorphism associations with type 2 diabetes, glucose, lipids, and cardiovascular disease incidence were modulated by MedDiet. RESEARCH DESIGN AND METHODS A randomized trial (two MedDiet intervention groups and a control group) with 7,018 participants in the PREvención con DIetaMEDiterránea study was undertaken and major cardiovascular events assessed. Data were analyzed at baseline and after a median follow-up of 4.8 years. Multivariable-adjusted Cox regression was used to estimate hazard ratios (HRs) for cardiovascular events. RESULTS The TCF7L2-rs7903146 polymorphism was associated with type 2 diabetes (odds ratio 1.87 [95% CI 1.62–2.17] for TT compared with CC). MedDiet interacted significantly with rs7903146 on fasting glucose at baseline (P interaction = 0.004). When adherence to the MedDiet was low, TT had higher fasting glucose concentrations (132.3 ± 3.5 mg/dL) than CC+CT (127.3 ± 3.2 mg/dL) individuals (P = 0.001). Nevertheless, when adherence was high, this increase was not observed (P = 0.605). This modulation was also detected for total cholesterol, LDL cholesterol, and triglycerides (P interaction < 0.05 for all). Likewise, in the randomized trial, TT subjects had a higher stroke incidence in the control group (adjusted HR 2.91 [95% CI 1.36–6.19]; P = 0.006 compared with CC), whereas dietary intervention with MedDiet reduced stroke incidence in TT homozygotes (adjusted HR 0.96 [95% CI 0.49–1.87]; P = 0.892 for TT compared with CC). CONCLUSIONS Our novel results suggest that MedDiet may not only reduce increased fasting glucose and lipids in TT individuals, but also stroke incidence.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-01-01 | Diabetes Care |